"Novo Nordisk's Breakthrough Weight-Loss Pill Sends Stock Soaring, Surpasses Tesla's Market Cap"
TL;DR Summary
Novo Nordisk's weight loss drugs Ozempic and Wegovy have been incredibly popular, with the company now teasing a new pill that could be twice as powerful as Wegovy. An early-stage trial found that an oral version of the drug amycretin led to users losing 13% of their body weight after 12 weeks of treatment, causing Novo Nordisk stock to surge to a record high. If successful, this new medication could lead to even faster weight loss and potentially make Novo Nordisk even more valuable than Tesla.
Topics:business#health-and-pharmaceuticals#novo-nordisk#ozempic#stock-market#wegovy#weight-loss-drug
- Novo Nordisk stock hits record on new weight loss drug trial Quartz
- Novo valuation surpasses Tesla on experimental obesity drug data Yahoo Finance
- Novo Nordisk surpasses Tesla's market cap Quartz
- Novo Nordisk shares jump 8% on promising weight loss trial results; Eli Lilly dips CNBC
- Novo Nordisk Surges After New Weight-Loss Pill Tops Wegovy Investor's Business Daily
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
71%
301 → 86 words
Want the full story? Read the original article
Read on Quartz